Advisors in Focus- February 28, 2021 - InvestingChannel

Advisors in Focus- February 28, 2021

Dear Advisor, 

Let’s be honest.

One thought occupies our waking hours – life returning to normal.

Saturday’s headline breathed life into the spirits of Americans across the nation.

The FDA granted an EUA (emergency use authorization) to Johnson and Johnson for the use and distribution of its COVID-19 vaccine. 

Although we expected the news, something fascinating popped up in our Trackstar data.

The top searches in the TrackStar surge category were dominated by pharmaceutical hopefuls

Market euphoria cooled last week at the prospect of rising rates. But, it wasn’t uniform.

Tech sector and its high valuations bore the brunt of the selling as it fell 4.9% for the week. 

Short squeeze names of the Reddit Rebellion like AMC Entertainment (AMC) and Gamestop (GME) topped the searches. Yet, they couldn’t muster anywhere close to the strength they saw weeks ago

Even electric vehicles names like Tesla (TSLA), Workhorse (WKHS), and Nio (NIO) struggled despite high search traffic among advisors and retail readers. 

However, it was the biopharma theme on the surge side that captivated stood out.

Johnson and Johnson news was already known – so to speak.

While the efficacy of their Covid vaccine delivers underwhelming 66% compared to the Moderna and Pfizer vax- 94% and 95%, respectively- it only requires a single-shot dose. That’s not to mention it can be transported at normal temperatures instead of ones cold enough to freeze a polar bear.

But the spike in search traffic in other pharmaceutical names seemed interesting.

So, we checked to see why these stocks garnered attention. 

Right now, retail speculation remains a key piece to the puzzle as the low floats attract the chat room-speculation crowd. 

Let’s take a look at a few top searches to sift through the contenders vs hopefuls.

TrackStarIQ Data

Here are some highlights from Retail searches this week –

RankTOP STOCKS – BY Retail (Total Traffic) This Past WeekTickerTOP STOCKS- BY RETAIL (Surge Traffic) This Past WeekTickerTOP ETFs By RETAIL (Total Traffic) This Past Week Ticker
1AMC Entertainment Holdings IncAMCTactical Services, Inc.TTSISPDR S&P 500 ETFSPY
2Churchill Capital Corp IV Cl ACCIVPandion Therapeutics IncPANDInvesco QQQQQQ
3Gamestop CorpGMELixte Biotechnology Holdings, Inc.LIXTARK Innovation ETFARKK
4Tesla IncTSLASensus Healthcare IncSRTSProShares Ultra VIX Short-Term FuturesUVXY
5Apple IncAAPLXtant Medical Holdings IncXTNTiShares Silver TrustSLV
6Palantir Technologies Inc Cl APLTRMalacca Straits Acquisition Company Ltd Cl AMLACProShares UltraPro QQQTQQQ
7Storage Computer CorpSOSOStereotaxis IncSTXSARK Fintech Innovation ETFARKF
8Sos LtdSOSAmeriserv FinancialASRVARK Genomic Revolution ETFARKG
9Workhorse GrpWKHSQuest Patent Research CorporationQPRCVanEck Vectors Semiconductor ETFSMH
10Nio IncNIORubius Therapeutics IncRUBYDirexion Daily Semiconductor Bull 3x SharesSOXL
11Ocugen IncOCGNAslan Pharmaceuticals Ltd ADRASLNiShares 20+ Year Treasury Bond ETFTLT
12Sundial Growers IncSNDLThe Graystone Company, Inc.GYSTTechnology Select Sector SPDR FundXLK
13Eversource EnergyESU.S. Physical TherapyUSPHEnergy Select Sector SPDR FundXLE
14Castor Maritime IncCTRMWisdom Homes of America, Inc.WOFAiShares Russell 2000 ETFIWM
15SquareSQDynatronics CpDYNTInvesco Solar ETFTAN
16Zomedica Pharmaceuticals CorpZOMIntrusion IncINTZProShares UltraPro Short QQQSQQQ IncAMZNArmstrong Flooring IncAFISPDR Gold TrustGLD
18Nvidia CorpNVDASilversun Technologies Inc Cl ASSNTiPath Series B S&P 500 VIX Short-Term Futures ETNVXX
19Visa IncVVPR Brands, LPVPRBARK Web x.0 ETFARKW
20AT&TTChromadex Corp CSCDXCiShares Global Clean Energy ETFICLN

Pandion Therapeutics is #2 on the Surge Traffic list and serves as the poster child for speculative dreams

PAND develops novel therapeutics to address the unmet needs of patients living with autoimmune diseases. 

On Thursday, Merck (MRK) announced it would buy the biotech firm for $60 a share, a tasty 140% premium. SVB Leerink Analyst Geoffrey Porges said in a note to clients, “This transaction also validates the notion that investors in recently public and early stage biopharma companies can still be tempted by the possibility by an early huge return from a large transaction at a high premium”. 

This is music to the speculator’s ears and drives a search for the ‘next PAND’.

Lixite Biotechnology (LIXT) is #3 on Surge Traffic

The stock ripped above the $4 level, hitting $7.20 before dropping a portion of its gains. 

What made this stock rally 50% you ask? 

Nothing… at least on the news front. LIXT did find itself at the center of social media discussions as the retail crowd is abuzz about a March 9 presentation at an H.C. Wainwright Global Life Sciences Conference. 

This name highlights the type of buzz we are seeing from the retail crowd over the past few weeks.

Sensus Healthcare (SRTS) came in #4 for Surge Traffic and presents a story we can sink our teeth into- a surprise earnings profit. 

SRTS distributes superficial radiation therapy devices to healthcare providers. 

On Thursday, the company delivered their quarterly results.

They posted a profit of 6 cents a share, 17 cents better than the dual analyst estimate of a loss of $11 cents per share. Revenues fell 40% from the prior year to $5.1 million but this was well above the expected $2.5 million in sales. 

COVID-19 hurt medical device makers, Sensus Healthcare included. But as the economy reopens, investors gravitate towards these elective procedure medical stocks as growth plays. 

Plus, Sensus sees an opportunity to use their superficial radiation therapy (SRT) systems to treat pneumonia in the lungs of Covid-19 patients. Pretty ingenious for a device designed to treat skin cancer.

SRTS is seeing a nice break above $4.40 resistance in reaction to the report. 

But before I let you go, let me throw one other stock to keep on your radar.

Xtant Medical (XTNT) came in at #5 on the Surge list. 

This is a medical technology company focused on surgical solutions for the treatment of spinal disorders. 

The company put out a release saying it was unaware of any developments that would have led to shares tripling in value on Friday. 

The company did announce the closing of a $20 million private placement on Thursday and this was enough to put it on the retail daytraders’ radar. 

XTNT carries a 4.19 million float and can be pushed around by this fast money. This is a target for the speculative wave crashing across penny stocks.

Related posts

Peers Reducing Beta in Uncertain Times


Can this Stock Ease Your Stress?


Advisors Looking East and Going for Gold


Market Showing Some Crox


Tech Earnings, Elections and Covid Oh My!


Commodities at the Forefront as Elections Loom